Trial Profile

A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Symptomatic Polycystic Liver Disease

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Jun 2025 According to Camurus media release, Based on the results of POSITANO Phase 2b study Camurus intends to discuss the design of a confirmatory Phase 3 study with regulatory authorities in the US and Europe.
18 Jun 2025 According to a Camurus media release, detailed results from the POSITANO study will be presented at future scientific meetings and in publications.
18 Jun 2025 Primary endpoint (Height-adjusted total liver volume (htTLV)) has been met as per the Camurus Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com